Key Highlights

  • Bruker shares closed down 21.79% at $50.30, after the company's second-quarter report revealed lowered full-year revenue guidance.
  • Second-quarter revenue of $838.5 million missed the $853.6 million analyst estimate by 1.77%, though non-GAAP EPS of $0.49 beat the $0.38 estimate.
  • The company lowered its full-year revenue guidance range to $3.54 billion to $3.57 billion, down from a prior range of $3.57 billion to $3.60 billion.
  • Investors reacted to a flagged $20 million shift of third-quarter revenue into the fourth quarter due to semiconductor customer delivery timing.
  • A GAAP diluted loss of $0.41 per share reflected a non-cash goodwill impairment in its automation and spatial biology businesses, alongside continued soft U.S. academic demand.

What Drove the Decline

Bruker (NASDAQ:BRKR) shares plunged 21.79% to close at $50.30, with a day range of $50.14 to $56.37 on volume of 8.82 million shares, after the company's second-quarter report revealed a lowered full-year revenue guidance range that overshadowed an otherwise mixed quarter.

Bruker is a Billerica, Massachusetts-headquartered leading global developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions used to explore life and materials at the microscopic, molecular, and cellular levels. The company operates through segments including Bruker Scientific Instruments Life Science, Bruker Nano, and Bruker Energy & Supercon Technologies, offering products spanning mass spectrometry, magnetic resonance, X-ray, and optical microscopy systems.

Second-quarter revenue was $838.5 million, up 5.2% year over year but missing the $853.6 million consensus estimate by 1.77%. Organic growth was 2.8%, or 3.4% excluding U.S. tariff refunds. Non-GAAP diluted EPS rose 53% to $0.49, beating the $0.38 estimate by 28.95%, aided by roughly $0.06 from net U.S. tariff refunds and cost savings. Scientific instrument segment bookings grew 10% organically, marking a fourth consecutive quarter with book-to-bill above 1.0.

Despite pockets of strength, including semiconductor metrology orders up more than 50% in the first half of the year and security detection orders up roughly 20% in the same period, the company flagged a $20 million shift of third-quarter revenue into the fourth quarter due to semiconductor customer delivery timing. A GAAP diluted loss of $0.41 per share reflected a non-cash goodwill impairment charge in the company's automation and spatial biology businesses, continued soft U.S. academic demand, and a low double-digit percentage decline in Asia-Pacific revenue.

Guidance and Restructuring

Bruker lowered its full-year 2026 revenue guidance to a range of $3.54 billion to $3.57 billion, representing 3% to 4% reported growth, down from a prior range of $3.57 billion to $3.60 billion. The company reaffirmed non-GAAP operating margin expansion of 250 to 300 basis points and non-GAAP EPS guidance of $2.10 to $2.15, representing 15% to 17% growth, though the reduced foreign exchange tailwind, cut to 0.5% from 1.5% previously due to a stronger dollar, is adding pressure to the outlook.

The company reorganized into four groups, Bruker Biosciences, Bruker Nano, BMD, and BEST, effective July 1, expected to generate an additional $20 million in cost savings in fiscal 2027, building on a $140 million annualized cost-saving target already underway for 2026, of which roughly $30 million was realized in the second quarter. For the third quarter, the company expects roughly flat to slightly up organic revenue, impacted by the semiconductor-related shift into the fourth quarter, and slightly lower sequential margins and EPS due to tariff refund timing pulled into the second quarter.

Bruker's market capitalization stood at $7.66 billion, with a trailing price-to-earnings ratio of 27.64 and a dividend yield of 0.40%. The stock's 52-week range spans $28.53 to $65.30, with today's decline pushing shares well off their recent highs.

Conclusion

Bruker's sharp decline reflects investor disappointment with lowered full-year guidance and a goodwill impairment charge, even as the company's core scientific instrument business showed genuine bookings momentum and margin expansion. With fourth-quarter results expected to show meaningful sequential improvement approaching $1 billion in quarterly revenue, driven by semiconductor deliveries and ultra-high-field NMR shipments, the stock's recovery will likely depend on the company delivering on that back-half acceleration.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.